SHPH

NASDAQ Healthcare

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Drug Manufacturers - Specialty & Generic

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.

🎯 投资策略评分

SHPH 在各投资策略中的评分。分数越高,越符合该策略目标。

高股息率 + 低波动性
高增长潜力(高贝塔 + 超卖)
逆向投资(超卖 + 低于移动均线)
超买股票(潜在做空标的)
🔍 策略解读

最佳匹配: 🔪 Falling Knife (99/100) — 此策略 逆向投资(超卖 + 低于移动均线).

评分最低的策略: 🎈 Over-Hyped (30/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →

在文本中查找 SHPH in your text

粘贴任何文章、记录或帖子 — 工具将提取 SHPH 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-05-01.